| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
J. Biol. Chem., Vol. 262, Issue 3, 988-991, 01, 1987
MC Starnes and YC Cheng
The nucleoside analog 2',3'-dideoxycytidine (ddCyd) has been shown to inhibit the infectivity and cytopathic effect of human immunodeficiency virus on human OKT4+ lymphocytes in vitro. Metabolism of ddCyd by human T-lymphoblastic cells (Molt 4) negative for human immunodeficiency virus and OKT4 was examined. Molt 4 cells accumulated ddCyd and its phosphorylated derivatives into acid-soluble and acid-insoluble material in a dose-dependent manner. For each concentration tested, 2',3'-dideoxycytidine triphosphate represented 40% of the total acid- soluble pool of ddCyd metabolites. Uptake of 5 microM ddCyd was linear for 4 h after addition of drug. Efflux of ddCyd metabolites from cells followed a biphasic course with an initial retention half-life of 2.6 h for 2',3'-dideoxycytidine triphosphate. DNA, but not RNA, of cells incubated with [3H]ddCyd became radiolabeled. Nuclease and phosphatase treatment of DNA followed by reverse-phase high pressure liquid chromatography showed that the nucleoside was incorporated into DNA in its original form. ddCyd was not susceptible to deamination by human Cyd-dCyd deaminase. It was a poor substrate for human cytoplasmic and mitochondrial dCyd kinases, with Km values of 180 +/- 30 and 120 +/- 20 microM, respectively. DNA polymerases alpha, beta, and gamma varied in their sensitivity to inhibition by ddCTP with Ki values of 110 +/- 40, 2.6 +/- 0.3, and 0.016 +/- 0.008 microM, respectively; however, inhibition was competitive with dCTP in each case.
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  T. Yeo, J Kintner, R Armand, R Perez, and L. Lewis Sublethal concentrations of gemcitabine (2',2'-difluorodeoxycytidine) alter mitochondrial ultrastructure and function without reducing mitochondrial DNA content in BxPC-3 human pancreatic carcinoma cells Human and Experimental Toxicology, December 1, 2007; 26(12): 911 - 921. [Abstract] [PDF]
|
|
|
|
 |
|
 E. Murakami, H. Bao, M. Ramesh, T. R. McBrayer, T. Whitaker, H. M. Micolochick Steuer, R. F. Schinazi, L. J. Stuyver, A. Obikhod, M. J. Otto, et al. Mechanism of Activation of {beta}-D-2'-Deoxy-2'-Fluoro-2'-C-Methylcytidine and Inhibition of Hepatitis C Virus NS5B RNA Polymerase Antimicrob. Agents Chemother., February 1, 2007; 51(2): 503 - 509. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. C. Keswani, C. Jack, C. Zhou, and A. Hoke Establishment of a Rodent Model of HIV-Associated Sensory Neuropathy J. Neurosci., October 4, 2006; 26(40): 10299 - 10304. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Reid, P. Wielinga, N. Zelcer, M. de Haas, L. van Deemter, J. Wijnholds, J. Balzarini, and P. Borst Characterization of the Transport of Nucleoside Analog Drugs by the Human Multidrug Resistance Proteins MRP4 and MRP5 Mol. Pharmacol., May 1, 2003; 63(5): 1094 - 1103. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. A. Brown and D. A. Clayton Release of replication termination controls mitochondrial DNA copy number after depletion with 2',3'-dideoxycytidine Nucleic Acids Res., May 1, 2002; 30(9): 2004 - 2010. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Balzarini, S. Aquaro, T. Knispel, C. Rampazzo, V. Bianchi, C.-F. Perno, E. De Clercq, and C. Meier Cyclosaligenyl-2',3'-didehydro-2',3'-dideoxythymidine Monophosphate: Efficient Intracellular Delivery of d4TMP Mol. Pharmacol., November 1, 2000; 58(5): 928 - 935. [Abstract] [Full Text]
|
|
|
|
|
|
J. Balzarini, L. Naesens, S. Aquaro, T. Knispel, C.-F. Perno, E. De Clercq, and C. Meier Intracellular Metabolism of CycloSaligenyl 3'-Azido-2',3'-dideoxythymidine Monophosphate, a Prodrug of 3'-Azido-2',3'-dideoxythymidine (Zidovudine) Mol. Pharmacol., December 1, 1999; 56(6): 1354 - 1361. [Abstract] [Full Text]
|
|
|
|
|
|
J. M. Adams, M. J. Shelton, R. G. Hewitt, M. DeRemer, R. DiFrancesco, T. H. Grasela, and G. D. Morse Zalcitabine Population Pharmacokinetics: Application of Radioimmunoassay Antimicrob. Agents Chemother., February 1, 1998; 42(2): 409 - 413. [Abstract] [Full Text]
|
|
|
|
|
|
J. Neyts, J. Balzarini, G. Andrei, Z. Chaoyong, R. Snoeck, A. Zimmermann, T. Mertens, A. Karlsson, and E. De Clercq Intracellular Metabolism of the N7-Substituted Acyclic Nucleoside Analog 2-Amino-7-(1,3-dihydroxy-2-propoxymethyl)purine, a Potent Inhibitor of Herpesvirus Replication Mol. Pharmacol., January 1, 1998; 53(1): 157 - 165. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Hentosh and M. Tibudan 2-Chloro-2'-deoxyadenosine, an Antileukemic Drug, Has an Early Effect on Cellular Mitochondrial Function Mol. Pharmacol., April 1, 1997; 51(4): 613 - 619. [Abstract] [Full Text]
|
|
|
|
 |
|
 M. Kukhanova, S.-H. Liu, D. Mozzherin, T.-S. Lin, C. K. Chu, and Y.-C. Cheng L- and D-Enantiomers of 2`,3`-Dideoxycytidine 5`-Triphosphate Analogs as Substrates for Human DNA Polymerases J. Biol. Chem., September 29, 1995; 270(39): 23055 - 23059. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y.-Z. Xu, P. Huang, and W. Plunkett Functional Compartmentation of dCTP Pools J. Biol. Chem., January 13, 1995; 270(2): 631 - 637. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H Mitsuya, R Yarchoan, and S Broder Molecular targets for AIDS therapy Science, September 28, 1990; 249(4976): 1533 - 1544. [Abstract] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Molecular and Cellular Proteomics |
| Journal of Lipid Research | ASBMB Today |
